Home » Stocks » BFRA

Biofrontera AG (BFRA)

Stock Price: $8.00 USD -0.17 (-2.08%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $8.04 +0.04 (0.50%) Jan 22, 5:55 PM
Market Cap 185.86M
Revenue (ttm) 35.13M
Net Income (ttm) -8.27M
Shares Out 44.63M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $8.00
Previous Close $8.17
Change ($) -0.17
Change (%) -2.08%
Day's Open 8.04
Day's Range 7.89 - 8.11
Day's Volume 21,475
52-Week Range 5.41 - 26.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported ...

GlobeNewsWire - 2 weeks ago

Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that ...

GlobeNewsWire - 1 month ago

Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malm...

GlobeNewsWire - 2 months ago

Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1....

Benzinga - 2 months ago

Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0...

GlobeNewsWire - 3 months ago

Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced o...

GlobeNewsWire - 3 months ago

Leverkusen, Germany, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports p...

GlobeNewsWire - 3 months ago

Leverkusen, Germany, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, reports the com...

GlobeNewsWire - 4 months ago

Leverkusen, Germany, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces th...

GlobeNewsWire - 4 months ago

Leverkusen, Germany, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceu...

Seeking Alpha - 4 months ago

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Leverkusen, Germany, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today publish...

GlobeNewsWire - 5 months ago

Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qua...

GlobeNewsWire - 5 months ago

Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be relea...

GlobeNewsWire - 5 months ago

Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,...

GlobeNewsWire - 5 months ago

Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced on July 27, 2020 the issuance of the 1.00% qualified subordinate...

GlobeNewsWire - 5 months ago

Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) has decided on 27 July 2020, with the approval of the Superv...

GlobeNewsWire - 5 months ago

Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Super...

GlobeNewsWire - 6 months ago

Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, toda...

GlobeNewsWire - 6 months ago

Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceut...

GlobeNewsWire - 6 months ago

Leverkusen, Germany, June 30, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirm...

GlobeNewsWire - 7 months ago

Leverkusen, Germany, May 28, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, an internation...

Seeking Alpha - 8 months ago

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its fina...

GlobeNewsWire - 8 months ago

Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical compan...

Seeking Alpha - 9 months ago

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today report...

GlobeNewsWire - 9 months ago

Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical comp...

GlobeNewsWire - 9 months ago

Leverkusen, Germany, April 17, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today report...

GlobeNewsWire - 9 months ago

Leverkusen, Germany, April 16, 2020 (GLOBE NEWSWIRE) -- The Annual General Meeting of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) shall be held on May 28, 2020. Today, the C...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 23, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, the Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible ...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced to...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) today signed a non-binding term sheet for an exclusive license agreement ...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 12, 2020 (GLOBE NEWSWIRE) -- On February 26, 2020, Management Board resolved to issue up to 1,600,000 of the 0.5% qualified subordinated mandatory convertible bond...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announ...

GlobeNewsWire - 10 months ago

Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has ent...

GlobeNewsWire - 11 months ago

Leverkusen, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provide...

GlobeNewsWire - 11 months ago

Leverkusen, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced tod...

GlobeNewsWire - 11 months ago

Leverkusen, Germany, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced tod...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announc...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announc...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announc...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announc...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced tod...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announc...

Seeking Alpha - 1 year ago

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announc...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceut...

GlobeNewsWire - 1 year ago

Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced th...

About BFRA

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the... [Read more...]

Industry
Biotechnology
IPO Date
Feb 14, 2018
CEO
Hermann Luebbert
Employees
155
Stock Exchange
NASDAQ
Ticker Symbol
BFRA
Full Company Profile

Financial Performance

In 2019, Biofrontera AG's revenue was 31.27 million, an increase of 48.13% compared to the previous year's 21.11 million. Losses were -7.36 million, -17.12% less than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Biofrontera AG stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is an increase of 50.00% from the latest price.

Price Target
$12.00
(50.00% upside)
Analyst Consensus: Strong Buy